mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

H. J. Prajapati, J. R. Spivey, S. I. Hanish, B. F. El-rayes, J. S. Kauh, Z. Chen, H. S. Kim

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)

Fingerprint

Medicine & Life Sciences